4KM Stock Chart & Stats
€0.09
<€0.01(2.35%)
At close: 4:00 PM EDT
€0.09
<€0.01(2.35%)
Day’s Range― - ―
52-Week Range€0.06 - €0.15
Previous CloseN/A
Volume0.00
Average Volume (3M)334.00
Market Cap
€45.01M
Enterprise Value€47.71M
Total Cash (Recent Filing)€4.16M
Total Debt (Recent Filing)€9.36M
Price to Earnings (P/E)52.4
Beta1.21
Next Earnings
Feb 02, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding655,299,900
10 Day Avg. Volume500
30 Day Avg. Volume334
Financial Highlights & Ratios
PEG Ratio-1.17
Price to Book (P/B)1.26
Price to Sales (P/S)2.53
P/FCF Ratio25.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)<0.01
Revenue Forecast (FY)€36.12M
Bulls Say, Bears Say
Bulls Say
Return To ProfitabilityThe return to profitability demonstrates meaningful operational improvement after several loss-making years. Although earnings weakened in 2026, maintaining positive net income provides a stronger base for reinvestment, customer development, and future recovery than the prior loss period.
Conservative LeverageModest leverage and a sizeable equity base give Kromek financial flexibility as it manages uneven operating performance. Lower debt burdens reduce pressure on cash resources and leave more capacity to support product development, customer programs, and recovery in demand.
Positive Free Cash FlowPositive free cash flow means the company continued generating cash after investment requirements despite a difficult year. This supports ongoing operations and reduces immediate reliance on external financing, while providing a foundation for rebuilding cash generation if profitability and revenue stabilize.
Bears Say
Revenue ContractionA sharp annual revenue decline signals weaker demand or delivery momentum across Kromek’s radiation detection activities. Sustained contraction would reduce operating leverage, make development spending harder to absorb, and challenge the company’s ability to convert its technology portfolio into consistent growth.
Margin CompressionThe substantial margin deterioration shows that recent profitability is vulnerable to changes in revenue mix, pricing, or operating costs. With net margin near break-even levels, even moderate further pressure could materially reduce earnings and limit internally funded investment.
Volatile Cash ConversionThe large fall in free cash flow indicates that cash generation has not yet become dependable, despite remaining positive. Such volatility can constrain long-term planning, reduce funding available for technology development, and increase sensitivity to fluctuations in customer deliveries or profitability.
Kromek Group plc News
4KM FAQ
What was Kromek Group PLC’s price range in the past 12 months?
Kromek Group PLC lowest stock price was €0.06 and its highest was €0.15 in the past 12 months.
What is Kromek Group PLC’s market cap?
Kromek Group PLC’s market cap is €45.01M.
When is Kromek Group PLC’s upcoming earnings report date?
Kromek Group PLC’s upcoming earnings report date is Feb 02, 2027 which is in 99 days.
How were Kromek Group PLC’s earnings last quarter?
Kromek Group PLC released its earnings results on Sep 14, 2026. The company reported -€0.005 earnings per share for the quarter.
Is Kromek Group PLC overvalued?
According to Wall Street analysts Kromek Group PLC’s price is currently Overvalued.
Does Kromek Group PLC pay dividends?
Kromek Group PLC does not currently pay dividends.
What is Kromek Group PLC’s EPS estimate?
Kromek Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kromek Group PLC have?
Kromek Group PLC has 655,299,900 shares outstanding.
What happened to Kromek Group PLC’s price movement after its last earnings report?
Kromek Group PLC reported an EPS of -€0.005 in its last earnings report. Following the earnings report the stock price went down -3.896%.
Which hedge fund is a major shareholder of Kromek Group PLC?
Currently, no hedge funds are holding shares in DE:4KM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kromek Group plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-17.71%
12-Months-Change
Fundamentals
Return on Equity
1.32%
Trailing 12-Months
Asset Growth
-5.04%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kromek Group PLC
Kromek Group plc, a UK-based entity established in 2013 with headquarters in Sedgefield, specializes in the design, production, and global distribution of advanced radiation detection components and devices. These technologies provide high-resolution data on material composition and structure, serving critical applications across diverse markets such as medical imaging, the civil nuclear sector, CBRNe security, and safety screening. Its reach extends across the United Kingdom, North America, Asia, Europe, Australasia, and Africa. The company's innovative solutions are employed for various purposes, from identifying cancerous tissues and hazardous substances like explosives, to analyzing radioactive materials. Within the civil nuclear industry, Kromek offers sophisticated gamma and neutron detectors, high-specification, high-resolution devices, essential components, and specialized software designed to address complex nuclear detection challenges. These often utilize cadmium zinc telluride (CZT) or scintillator technologies for the detection of gamma rays, x-rays, and neutrons. For medical imaging, their portfolio includes CZT gamma detectors for SPECT, CZT bone mineral densitometry detectors, and cutting-edge photon-counting spectral CT systems. Kromek also provides CBRNE homeland security products and comprehensive solutions for a wide range of clients, including government agencies, border control, airports, seaports, HazMat teams, ambulance crews, police, and armed forces. This offering features specialized gamma spectroscopy software for in-depth sample analysis. Furthermore, the company supports scientific research and development through its CZT imaging development platforms, such as the DMatrix and the EV3500 scalable x-ray CZT linear array, designed for laboratory and research applications. Kromek distributes its products through a combination of distributors, original equipment manufacturers (OEMs), and direct sales channels.






